Recently, we evaluated the capacity of Cp 090104 and CP-derived BLPs, when co-administered with the pneumococcal vaccine Prevenar®13 via the nasal route, to improve the protection of mice against pneumococcal infection [13]. Here, CP is linked to pneumococcal infection.